Skip to main content

Security report for angelinipharma.fr

Angelini Pharma France · Healthcare · France

Low risk. 3 critical or high findings in GDPR outside view, Email security and 1 other check.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma France is a medium-sized pharmaceutical company specializing in central nervous system disorders, including epilepsy and rare diseases. The company is part of the larger Angelini S.p.a. group and operates primarily in France and Italy. The website presents a professional image with clear business information, a focus on healthcare expertise, and partnerships. The digital infrastructure uses modern JavaScript libraries and analytics tools, with good mobile optimization and SEO practices. Security posture is solid with HTTPS and no visible vulnerabilities, though some security headers and incident response information are missing. Privacy compliance is well addressed with clear policies and cookie consent mechanisms. The absence of WHOIS data is a concern but does not outweigh the overall legitimacy of the site. Strategic recommendations include enhancing security headers, publishing incident response contacts, and improving accessibility.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • High

      No DMARC record found

      DMARC provides email authentication and reporting

      What to do: Add DMARC record: "v=DMARC1; p=none; rua=mailto:dmarc@yourdomain.com"

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.fr

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
90
Email security
65
DNS health
70
Network security
100
GDPR outside view
68
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma holds a strong market position in the pharmaceutical healthcare sector, focusing on neuroscience and epilepsy treatments. Their business model includes research, product development, and strategic partnerships, particularly in France. The company leverages its parent company Angelini Industries for broader market reach. The website reflects a mature digital presence with good content quality and trust indicators such as certifications and clear legal information. The partnership ecosystem includes related domains like the global Angelini Pharma site and the parent company. Growth indicators include active content updates and compliance with European privacy regulations.

Security posture

The website demonstrates a good security posture with enforced HTTPS and no exposed sensitive data. However, the lack of explicit security headers such as Content Security Policy (CSP), HSTS, and X-Frame-Options reduces the overall security hardening. No incident response or vulnerability disclosure information is provided, which is a gap in security transparency. The use of reputable analytics tools like Piwik PRO indicates attention to privacy compliance. No vulnerable libraries or insecure forms were detected. Overall, the site is secure but could improve in transparency and header configurations.

Recommendations

  1. Implement and enforce security headers including CSP, HSTS, and X-Frame-Options to enhance protection against common web attacks.
  2. Publish clear incident response and vulnerability disclosure information to improve security transparency and readiness.
  3. Enhance accessibility features to comply with WCAG standards and improve user experience for all visitors.
  4. Provide direct company contact emails and phone numbers on the website to improve business credibility and user trust.
  5. Regularly audit third-party scripts and analytics tools to ensure no vulnerabilities or privacy issues arise.

Contact details published on the site

Addresses
Legal name
Angelini Pharma France
VAT number
FR69901642470
Registration number
901 642 470 00024
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma France
Description
Angelini Pharma is a pharmaceutical company focused on improving product quality and patient life, with expertise in central nervous system diseases including epilepsy and rare diseases. It is a recognized and reliable company with a strong presence in Italy and France.
Key services
Neurosciences research, Epilepsy treatment, Partnerships with healthcare organizations
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Carousel, Magnific Popup, Flip.js, Piwik PRO analytics
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • Use of async loading for analytics scripts

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO analytics
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in French.
  2. No WAF or security challenge detected.
  3. WHOIS data is missing, which is unusual but not necessarily malicious.
  4. Strong focus on healthcare and pharmaceutical expertise.
  5. Good compliance with privacy and cookie policies including consent mechanisms.
  6. No direct company emails or phone numbers found in the visible content.
  7. Contact form is available via /nous-contacter/ page.
  8. Use of modern JavaScript libraries and analytics tools.
  9. No visible security.txt or incident response info.
  10. Certifications include Top Employer Europe 2025 badge.
Technical notes

Notes

The website uses a modern JavaScript stack including jQuery 3.7.1, Slick Carousel, Magnific Popup, and Flip.js for UI components. Analytics are handled via Piwik PRO with asynchronous loading to minimize performance impact. The site is mobile optimized with responsive design and good SEO meta tags including Open Graph and Twitter cards. No CMS or hosting provider is explicitly detected. Performance is moderate with room for improvement in loading speed and accessibility. The absence of CMS may indicate a custom or static site architecture. Technical debt appears low, but security header implementation is lacking.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.fr. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.fr.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.